Breaking News

ARCA Biopharma’s AB201 for COVID-19 Gets Fast Track

Initiation of ASPEN-COVID-19 Phase 2b clinical trial anticipated in December with trial data anticipated 2Q21.

By: Contract Pharma

Contract Pharma Staff

ARCA biopharma, Inc., a company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, received Fast Track designation from the FDA for AB201 as a potential treatment for COVID-19. The company plans to initiate a Phase 2b clinical trial (ASPEN-COVID-19) of AB201 in approximately 100 patients hospitalized with COVID-19 in December 2020, with topline trial data anticipated in 2Q21. Fast Track programs are designed to facilitate the deve...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters